SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing of its first patient in a Phase 2 atopic dermatitis study, with their lead compound DMT210. DMT210 is a novel anti-inflammatory topical gel targeting multiple cytokines in the skin responsible for the itchy, red, swollen and cracked skin seen in most atopic dermatitis patients.
This clinical trial, DMT210-002, is a 28-day Phase 2, multi-center, double-blind, vehicle controlled study designed to evaluate the safety, tolerability and efficacy of twice daily dosing of DMT210 in 25 mild to moderate atopic dermatitis patients. The efficacy will be measured by the individual signs and symptoms of atopic dermatitis, investigator’s global assessment, and Atopic Dermatitis Severity Index. Dermata expects to have top line results in the first half of 2017.
“Adults and children are seeking better and safer treatments for their atopic dermatitis because it significantly affects their daily lives, including interrupting sleep, disturbing work or school and causing social anxiety,” states Gerald Proehl, President and CEO of Dermata. “We hope that DMT210 can be a safe and effective first-line therapy to help alleviate the daily struggles these patients suffer from and allow them to live a more normal life.”
About DMT210: DMT210 is a topical aqueous gel, containing a new chemical entity (NCE), which belongs to a class of compounds called Isoprenylcysteines (IPCs). This NCE is a G-protein modulator, designed as a structural mimic of the amino acid tail found at the C-terminus of G-proteins to reduce inflammation and erythema by blocking multiple cell signaling pathways. Because of DMT210’s effect on multiple inflammatory pathways, Dermata plans to develop the product for multiple diseases.
About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.
CONTACT: | Dermata Contact |
Gerald Proehl | |
President and CEO | |
858.223.0888 | |
Logo - http://photos.prnewswire.com/prnh/20160512/367116LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-announces-initiation-of-treatment-in-a-phase-2-atopic-dermatitis-study-300365222.html
SOURCE Dermata Therapeutics, LLC
